Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
- Category: Small Molecules
- Published on Saturday, 12 September 2020 14:05
- Hits: 1632
- Data Demonstrated that Newly Approved ONGENTYS Significantly Reduced "Off" Time as an Add-On Therapy in Patients with Parkinson's Disease Taking Levodopa/Carbidopa only in a Pooled Post-Hoc, Sub-Group Analysis of Phase III Studies
- ONGENTYS Significantly Increased "On" Time When Used as the First COMT-Inhibitor Add-On Therapy Compared with Entacapone in Recently Diagnosed Patients with Motor Fluctuations in Post-Hoc Analysis from a Phase III Study
- Real-World Data Highlight the Impact of Motor Fluctuations Experienced by Patients with Parkinson's Disease Have on the U.S. Healthcare System
SAN DIEGO, CA, USA I September 11, 2020 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS® (opicapone) capsules decreased "off" time and increased "on" time without troublesome dyskinesia as an add-on therapy to levodopa/carbidopa in patients with Parkinson's disease who experience motor fluctuations. Neurocrine Biosciences also presented real-world data showing the increased burden motor fluctuations have over time on Parkinson's disease patients and the healthcare system through significantly more hospitalizations and emergency room visits. These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 12–16 (www.mdscongress.org/Congress/Registration.htm).
ONGENTYS, approved by the U.S. Food and Drug Administration in April 2020, is the first and only once-daily catechol-O-methyltransferase (COMT) inhibitor approved as an add-on to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes and will be available to wholesalers in September.
"As Parkinson's disease progresses and treatment with levodopa/carbidopa begins to wear off between treatment doses, many patients begin to experience increased motor fluctuations," said Robert A. Hauser, M.D., Professor of Neurology and Director, University of South Florida Parkinson's Disease and Movement Disorders Center. "The Phase III post-hoc data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa in patients with Parkinson's disease who have motor fluctuations. Patients with Parkinson's disease now have a new treatment option to help provide more control of motor symptoms."
Data from a pooled post-hoc, sub-group analysis of Phase III studies demonstrated that ONGENTYS 50 mg significantly reduced "off" time by more than an hour compared to placebo when used as an add-on treatment in patients with Parkinson's disease treated with levodopa/carbidopa plus placebo at baseline (109.2 minutes for ONGENTYS 50 mg [n=67] vs. 40.3 minutes for placebo [n=59]; p=0.0161).
In a separate post-hoc analysis, ONGENTYS significantly increased absolute "on" time by approximately one additional hour compared with entacapone (124 minutes [n=50] vs. 60 minutes [n=47]; p=0.0344) when used as the first COMT inhibitor add-on therapy to levodopa/carbidopa in patients with Parkinson's disease recently diagnosed with motor fluctuations.
"These data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa earlier in the treatment regimen of patients with Parkinson's disease. In addition to decreasing 'off' time the data also show that ONGENTYS significantly increased 'on' time compared to an older COMT inhibitor to help control motor fluctuations in patients with Parkinson's disease," said Eiry W. Roberts, MD, Chief Medical Officer, Neurocrine Biosciences. "We are looking forward to bringing ONGENTYS to patients as a new add-on treatment option as data from our real-world study show that the debilitating symptoms of Parkinson's disease result in more hospitalizations and emergency room visits, impacting the healthcare system in the U.S."
Neurocrine Biosciences also presented real-world data from a retrospective medical chart review of adult patients with Parkinson's disease who began experiencing motor fluctuations while taking levodopa. Of the 310 patients included in the review, 117 (38%) had a history of motor fluctuations of ≥ 2 years. Data show that emergency department visits were significantly more frequent in patients with Parkinson's disease with a longer history of motor fluctuations (≥2 years) compared to patients with a shorter history (13% [n=15] vs. 3% [n=5]; P<0.001). Similarly, hospitalizations were significantly more frequent in patients with a longer history of motor fluctuations (15% [n=18] vs 6% [n=12], P<0.01). Among patients who were hospitalized, the mean length of stay was shorter in patients with motor fluctuations ≥2 years versus patients with motor fluctuations <2 years, but the difference was not statistically significant (0.5 vs 1.1 days; P>0.05).
About the BIPARK-1 Study
BIPARK-1 was a Phase III, randomized, double-blind placebo- and active-controlled study of ONGENTYS as an adjunct to levodopa therapy in which approximately 600 patients with Parkinson's disease and motor fluctuations received once-daily doses of opicapone (5 mg, 25 mg, or 50 mg), placebo, or 200 mg doses of the COMT inhibitor entacapone for 14 to 15 weeks. The primary endpoint was the change from baseline in absolute time in the "off" state, as assessed by patient diaries. The initial study period was followed by a one-year open-label phase during which all patients received treatment with opicapone.
About the BIPARK-2 Study
BIPARK-2 was a Phase III, randomized, double-blind placebo-controlled study of opicapone as an adjunct to levodopa therapy in which approximately 400 patients with Parkinson's disease and motor fluctuations received once-daily doses of opicapone (25 mg or 50 mg) or placebo for 14 to 15 weeks. The primary endpoint was the change from baseline in absolute time in the "off" state, as assessed by patient diaries. The initial study period was followed by a one-year open-label phase during which all patients received treatment with opicapone.
BIPARK-1 and BIPARK-2 were conducted by BIAL – Portela & CA, S.A. (BIAL). Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada. BIAL received approval from the European Commission for ONGENTYS as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. BIAL currently markets ONGENTYS in Germany, United Kingdom, Spain, Portugal and Italy.
About Parkinson's Disease
Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disorder that affects approximately one million people in the United States and six million people worldwide. Parkinson's disease is associated with low dopamine levels produced in the brain. Dopamine helps transmit signals between the areas of the brain that control all purposeful movements, including talking, walking and writing. As Parkinson's disease progresses, dopamine production steadily decreases, resulting in increased problems with motor symptoms including slowed movement (bradykinesia), tremor, rigidity, impaired posture and balance, and difficulty with speech and writing.
There is presently no cure for Parkinson's disease and management of the disease consists of the use of treatments that attempt to control motor symptoms primarily through dopaminergic mechanisms. The current gold standard for treatment of motor symptoms is levodopa/carbidopa. While levodopa/carbidopa improves patients' motor symptoms, as the disease progresses, the beneficial effects of levodopa begin to wear off more quickly. Patients then experience motor fluctuations throughout the day between "on" time, periods when the medication is working and Parkinson's disease symptoms are controlled, and "off" time, when the medication is not working, and motor symptoms return.
About ONGENTYS® (opicapone) Capsules
ONGENTYS is a unique, once-daily, oral, peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. ONGENTYS inhibits the COMT enzyme, which breaks down levodopa, making more levodopa available to reach the brain.
ONGENTYS® (opicapone) capsules is a prescription medicine used with levodopa and carbidopa in people with Parkinson's disease (PD) who are having "OFF" episodes.
It is not known if ONGENTYS is safe and effective in children.
Please see ONGENTYS full Product Information.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
SOURCE: Neurocrine Biosciences